Proteomics International’s OxiDx Faces Competitive Pressure Despite Patent Expansion
Proteomics International Laboratories has secured a key Chinese patent for its OxiDx oxidative stress test, broadening its intellectual property coverage across major global markets until 2039. This milestone reinforces the company’s position in precision diagnostics for sports and veterinary health.
- Chinese patent granted for OxiDx technology valid until 2039
- Patent complements existing protections in USA, Japan, Europe, and Australia
- OxiDx measures oxidative stress via a simple fingerprick blood test
- Technology targets muscle injury detection in high-performance sports and horse racing
- Oxidative stress linked to over 70 health conditions, including sports injuries
Global Patent Expansion Strengthens OxiDx’s Market Position
Proteomics International Laboratories Ltd (ASX: PIQ) has announced a significant intellectual property milestone with the granting of a Chinese patent for its OxiDx technology. This patent, valid until March 2039, extends the company’s protection of its innovative oxidative stress measurement platform into one of the world’s largest healthcare markets. It complements existing patents in the USA, Japan, Europe, and Australia, solidifying OxiDx’s global footprint.
Innovative Technology with Broad Health Implications
The OxiDx test offers a simple yet precise method to assess oxidative stress through a fingerprick blood sample. Oxidative stress, caused by an imbalance between free radicals and antioxidants, is implicated in over 70 health conditions, ranging from chronic diseases to acute muscle injuries. By detecting protein biomarkers indicative of oxidative damage, OxiDx provides valuable insights into an individual’s or animal’s health status.
Targeting High-Performance Sports and Equine Health
Muscle injuries represent a major challenge in professional sports, accounting for up to 55% of all injuries. Similarly, the horse racing industry faces a high incidence of injuries, with 85% of thoroughbreds affected during their early racing seasons. OxiDx’s ability to monitor muscle damage and recovery through a minimally invasive test positions it as a valuable tool for athletes and trainers seeking to optimize performance and reduce downtime.
Strategic IP Protection and Commercial Outlook
The newly granted Chinese patent (ZL201980022119.X) is part of a second generation of patents that enhance the original protections valid until 2026 and 2028 in Australia and the USA, respectively. Additional patent applications are pending in the USA, Singapore, and India, indicating a strategic approach to securing global rights. While immediate commercial contracts in China have not been disclosed, this patent strengthens Proteomics International’s position to capitalize on growing demand for precision diagnostics in Asia.
Collaboration and Innovation at the Forefront
Developed in collaboration with The University of Western Australia, OxiDx exemplifies the intersection of academic research and commercial innovation. As a 66% owned subsidiary of Proteomics International, OxiDx continues to advance its technology platform, aiming to expand applications beyond sports and veterinary health into broader medical diagnostics.
Bottom Line?
With patent protection now secured in China, Proteomics International is poised to deepen its global reach in oxidative stress diagnostics, setting the stage for future commercial breakthroughs.
Questions in the middle?
- How soon will Proteomics International commercialize OxiDx in the Chinese market?
- What are the prospects for regulatory approvals and reimbursement in key jurisdictions?
- How will emerging competitors impact OxiDx’s market share in oxidative stress testing?